<DOC>
	<DOCNO>NCT01849289</DOCNO>
	<brief_summary>This trial conduct Africa , Asia , Europe , North South America . The aim trial compare efficacy safety insulin degludec insulin glargine insulin naïve subject type 2 diabetes .</brief_summary>
	<brief_title>A Trial Comparing Efficacy Safety Insulin Degludec Insulin Glargine Insulin naïve Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes mellitus ( diagnose clinically ) least 6 month Insulin naïve subject ( Allowed : previous short term insulin treatment 14 day ; treatment hospitalisation gestational diabetes allow period longer 14 day ) Current treatment : metformin monotherapy metformin combination insulin secretagogue ( sulfonylurea glinide ) , dipeptidyl peptidase IV ( DPPIV ) inhibitor , alfaglucosidaseinhibitors ( acarbose ) unchanged dose least 3 month prior randomisation ( Visit 2 ) minimum dos state : metformin : alone combination ( include fix combination ) 1500 mg daily , maximum tolerate dose ( least 1000 mg daily ) , insulin secretagogue ( sulfonylurea glinide ) : minimum half daily maximal dose accord local labelling , DPPIV inhibitor : minimum 100 mg daily accord local labelling , alfaglucosidaseinhibitors ( acarbose ) : minimum half daily maximal dose maximum tolerated dose HbA1c ( glycosylated haemoglobin ) 7.010.0 % ( inclusive ) central laboratory analysis BMI ( Body Mass Index ) equal 40.0 kg/m^2 Treatment TZDs ( thiazoledinedione ) , GLP1 ( glucagonlike peptide 1 ) receptor agonist within last 3 month prior Visit 1 ( screen ) Anticipated change concomitant medication know interfere significantly glucose metabolism , systemic corticosteroid , betablockers , MAO ( monoamine oxidase ) inhibitor Cardiovascular disease within last 6 month prior Visit 1 ( screen ) define stroke ; decompensated heart failure NYHA ( New York Heart Association ) class III IV ; myocardial infarction ; unstable angina pectoris ; coronary arterial bypass graft angioplasty Any clinically significant disease disorder , except condition associate type 2 diabetes mellitus , Investigator 's opinion could interfere result trial Previous participation trial . Participation define randomise . Rescreening screen failure allow within limit recruitment period Known suspect hypersensitivity trial product ( ) relate product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>